BidaskClub lowered shares of Clovis Oncology (NASDAQ:CLVS) from a sell rating to a strong sell rating in a research note issued to investors on Friday.

A number of other research analysts have also recently weighed in on the company. Barclays started coverage on Clovis Oncology in a report on Monday, October 23rd. They issued an overweight rating and a $105.00 target price on the stock. Stifel Nicolaus reiterated a buy rating and issued a $125.00 target price on shares of Clovis Oncology in a report on Friday, November 3rd. Zacks Investment Research upgraded Clovis Oncology from a hold rating to a buy rating and set a $95.00 target price on the stock in a report on Tuesday, October 17th. Leerink Swann reissued an outperform rating and issued a $90.00 price objective (down from $107.00) on shares of Clovis Oncology in a research report on Wednesday, November 15th. Finally, Morgan Stanley cut their price objective on Clovis Oncology from $89.00 to $86.00 and set an overweight rating on the stock in a research report on Thursday, November 2nd. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the company’s stock. Clovis Oncology currently has an average rating of Hold and an average target price of $90.43.

Shares of Clovis Oncology (NASDAQ:CLVS) traded up $0.89 during trading on Friday, reaching $56.76. The company had a trading volume of 842,609 shares, compared to its average volume of 1,260,000. Clovis Oncology has a 52-week low of $45.42 and a 52-week high of $99.45. The firm has a market capitalization of $2,830.00, a PE ratio of -6.86 and a beta of 1.38. The company has a quick ratio of 3.16, a current ratio of 3.19 and a debt-to-equity ratio of 0.94.

Clovis Oncology (NASDAQ:CLVS) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.18) by ($0.06). Clovis Oncology had a negative net margin of 947.47% and a negative return on equity of 122.06%. The firm had revenue of $16.81 million during the quarter, compared to analyst estimates of $21.12 million. During the same quarter in the previous year, the business posted ($1.70) EPS. analysts predict that Clovis Oncology will post -7.65 EPS for the current fiscal year.

In other news, Director Thorlef Spickschen sold 4,500 shares of Clovis Oncology stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $64.97, for a total transaction of $292,365.00. Following the sale, the director now directly owns 21,118 shares of the company’s stock, valued at $1,372,036.46. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Gillian C. Ivers-Read sold 3,000 shares of Clovis Oncology stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $63.70, for a total value of $191,100.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 18,000 shares of company stock worth $1,123,425. Corporate insiders own 12.50% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Phocas Financial Corp. acquired a new position in Clovis Oncology in the second quarter worth about $112,000. Capital Analysts LLC acquired a new position in Clovis Oncology in the third quarter worth about $111,000. Cypress Capital Management LLC WY grew its stake in Clovis Oncology by 272.7% in the third quarter. Cypress Capital Management LLC WY now owns 2,050 shares of the biopharmaceutical company’s stock worth $169,000 after purchasing an additional 1,500 shares in the last quarter. Stevens Capital Management LP acquired a new position in Clovis Oncology in the second quarter worth about $257,000. Finally, PNC Financial Services Group Inc. grew its stake in Clovis Oncology by 0.7% in the second quarter. PNC Financial Services Group Inc. now owns 2,820 shares of the biopharmaceutical company’s stock worth $265,000 after purchasing an additional 20 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: “Clovis Oncology (CLVS) Stock Rating Lowered by BidaskClub” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/clovis-oncology-clvs-stock-rating-lowered-by-bidaskclub/1815972.html.

About Clovis Oncology

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.